Evidence map›Paper›PMID 35024909›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2022

Pycnogenol ameliorates motor function and gene expressions of NF-ƙB and Nrf2 in a 6-hydroxydopamine-induced experimental model of Parkinson's disease in male NMRI mice.

Farajollah Jafari, Mahdi Goudarzvand, Ramin Hajikhani, Mostafa Qorbani, Jalal Solati

Abstract read
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Farajollah JafariDepartment of Biology, Faculty of Life Sciences, Islamic Azad University, North Tehran Branch, Tehran, Iran.ORCID http://orcid.org/0000-0002-9837-8954
Mahdi GoudarzvandDepartment of Physiology and Pharmacology, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran. m.godarzvand@abzums.ac.ir.ORCID http://orcid.org/0000-0002-4229-5148
Ramin HajikhaniDepartment of Biology, Faculty of Biological Sciences, Islamic Azad University, North Tehran Branch, Tehran, Iran.
Mostafa QorbaniNon-Communicable Diseases Research Center, Alborz University of Medical Sciences, Karaj, Iran.
Jalal SolatiDepartment of Biology, Faculty of Basic Sciences, Islamic Azad University, Karaj Branch, Karaj, Iran.
Islamic Azad University North Tehran Branch · IRJahrom University of Medical Sciences · IRIslamic Azad University, Karaj · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We investigated the effect of Pycnogenol as an antioxidant on improving motor function, depression, and the expression of NF-ƙB and Nrf2 genes in the experimental model of Parkinson's disease. Forty adult male NMRI mice weighing about 30 g were randomly divided into five groups of eight. Saline group: received 3 μl of saline, as 6-hydroxydopamine (6-OHDA) solvent, unilaterally in the left striatum, treatment groups: first received 3 µl 6-OHDA unilaterally inside the ipsilateral striatum and then divided into subgroup A: received distilled water, Pycnogenol solvent, by gavage for 7 days (lesion group), and subgroup B: received Pycnogenol at doses of 10, 20, and 30 mg/kg by gavage for 7 days. Seven days after Parkinson's model induction, the apomorphine test, the degree of catalepsy by bar test, the duration of immobility (depression) by forced swimming test (FST) were measured. In addition, the expression of NF-ƙB and Nrf2 genes was measured using the real-time PCR technique. The total number of rotations in the apomorphine test decreased significantly in the groups receiving Pycnogenol. Administration of Pycnogenol significantly reduced catalepsy. The study of depression in the group receiving Pycnogenol showed a significant reduction. Also, Pycnogenol increased the expression of the Nrf2 anti-inflammatory gene, but it had no significant difference in the expression of NF-ƙB gene. Pycnogenol, presumably with its antioxidative and genomic effects, improves the expression of the anti-inflammatory gene and found that neuroprotection effect in the brain.

Indexed as

AnimalsAntioxidantsApomorphineDose-Response Relationship, DrugFlavonoidsGene Expression RegulationMaleMiceNeuroprotective AgentsNF-E2-Related Factor 2NF-kappa BOxidopamineParkinsonian DisordersPlant ExtractsAntioxidantsApomorphineFlavonoidsNeuroprotective AgentsNfe2l2 protein, mouseNF-E2-Related Factor 2NF-kappa BOxidopaminePlant ExtractspycnogenolsGene expressionMotor functionParkinson’s diseasePycnogenol

Identifiers

PMID35024909
OpenAlexW4206709496

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.